Evidence map›Paper›PMID 36469155›Full record

ArticleJournal of cancer research and clinical oncology2023

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.

Karin G Schrenk, Wolfram Weschenfelder, Christian Spiegel, Abbas Agaimy, Robert Stöhr, Arndt Hartmann, Nikolaus Gaßler, Robert Drescher, Martin Freesmeyer, Amer Malouhi and 7 more

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. [AJNR. American journal of neuroradiology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Karin G SchrenkDepartment of Hematology and Internal Oncology, Clinic of Internal Medicine II, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. karin.schrenk@med.uni-jena.de.
Wolfram WeschenfelderClinic of Trauma-, Hand- and Reconstructive Surgery, University Hospital Jena, Jena, Germany.
Christian SpiegelClinic of Trauma-, Hand- and Reconstructive Surgery, University Hospital Jena, Jena, Germany.
Abbas AgaimyInstitute of Pathology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Robert StöhrInstitute of Pathology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Arndt HartmannInstitute of Pathology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Nikolaus GaßlerInstitute of Forensic Medicine, Section of Pathology, University Hospital Jena, Jena, Germany.
Robert DrescherClinic of Nuclear Medicine, University Hospital Jena, Jena, Germany.
Martin FreesmeyerClinic of Nuclear Medicine, University Hospital Jena, Jena, Germany.
Amer MalouhiInstitute of Diagnostic and Interventional Radiology, University Hospital Jena, Jena, Germany.
Florian BürckenmeyerInstitute of Diagnostic and Interventional Radiology, University Hospital Jena, Jena, Germany.
René AschenbachInstitute of Diagnostic and Interventional Radiology, University Hospital Jena, Jena, Germany.
Ulf TeichgräberInstitute of Diagnostic and Interventional Radiology, University Hospital Jena, Jena, Germany.
Christine KöglerClinic of General- and Visceral Surgery, Malteser Hospital St. Marien, Erlangen, Germany.
Matthias VogtClinic in the Medicenter PartGmbB, Erlangen, Germany.
Gunther O HofmannClinic of Trauma-, Hand- and Reconstructive Surgery, University Hospital Jena, Jena, Germany.
Andreas HochhausDepartment of Hematology and Internal Oncology, Clinic of Internal Medicine II, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
Jena University Hospital · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEMedice (Germany) · DEUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET-fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients.

Indexed as

Lung NeoplasmsSarcomaSoft Tissue NeoplasmsHumansNeoadjuvant TherapyProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolesPyridinesTranscription FactorsProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolesPyridinesRET protein, humanselpercatinibTranscription FactorsTRIM33 protein, humanRET-fusionSarcomaSelpercatinibTargeted therapyTRIM33

Identifiers

PMID36469155
PMCPMC10356868
OpenAlexW4310705924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.